Trials / Sponsors / Thryv Therapeutics, Inc.
Thryv Therapeutics, Inc.
Industry · 6 registered clinical trials — 2 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Recruiting | Evaluation of Efficacy and Safety of THRV-1268 in Long QT Syndrome Type 2 (LQTS 2) Long QT Syndrome (LQTS) 2 | Phase 2 / Phase 3 | 2026-03-31 |
| Recruiting | Observational Study to Describe Health-Related Quality of Life and Measure Disease Burden Among Patients With Long QT Syndrome Type 3, Long QT Syndrome 2 | — | 2025-10-27 |
| Completed | Phase 1, Single Ascending Dose Study to Evaluate the Safety, Tolerability, PK, PD, and Comparative Bioavailabi Heart Failure | Phase 1 | 2025-09-15 |
| Completed | Study to Assess the Safety, Tolerability, Pharmacokinetic of Thrv-1268 Atrial Fibrillation | Phase 1 | 2024-05-15 |
| Terminated | Study of LQT-1213 on QTc-induced Prolongation in Healthy Adult Subjects (Part1) and on Congenital Long QT in P Long QT Syndrome | Phase 1 / Phase 2 | 2023-03-12 |
| Completed | Phase 1 Study of LQT-1213 in Healthy Adults Long QT Syndrome | Phase 1 | 2022-09-14 |